OPTIMAL
L’Ente Capofila del progetto è Fondazione IRCCS Istituto Nazionale dei Tumori. Il Responsabile Scientifico del progetto è il Professor Paolo Corradini.
| Patologia: | linfoma a grandi cellule B |
| Area Tematica: | Medicina di Precisione e Innovazione tecnologica |
| Data di Inizio Progetto: | 01.02.2026 |
| Data di Fine Progetto: | 31.01.2029 |
| Finanziamento: | € 2.000.000,00 |
| Partenariato | Fondazione IRCCS Istituto Nazionale dei Tumori IRCCS Istituto Clinico Humanitas IRCCS Istituto Europeo di Oncologia Fondazione IRCCS Policlinico San Matteo |
T-cell redirecting therapies, such as chimeric antigen receptor (CAR) T cells and bispecific T-cell-engaging antibodies (BsAbs), have transformed the outcomes for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). However, 55-60% of patients are not cured by CAR T-cell therapy, and some can be salvaged with BsAbs or allogeneic stem cell transplants. The absence of reliable biomarkers for predicting therapeutic responses, tracking disease, and understanding resistance, limits optimal decision-making and healthcare sustainability. To address these challenges, we have designed a prospective study of 180 LBCL patients treated with CD19 CAR T cells, with half receiving BsAbs after relapse or refractory disease. An additional cohort of roughly 50 patients ineligible for CAR T therapy that will receive BsAbs alone, will be studied. This project aims to identify biomarkers that guide patient selection, optimize therapy sequencing, and personalize treatment through advanced therapeutic algorithms driven by explainable artificial intelligence (XAI). This project could improve outcomes and sustainability by providing more effective and individualized therapies for LBCL patients.